Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13626168 | 0.82 | POLB (0.39) | POLBTRPA1 | |
| SCHEMBL13611898 | 0.82 | POLB (0.39) | POLBTRPA1 | |
| SCHEMBL154812 | 0.79 | POLB (0.46) | POLBKDM4EALDH1A1 | |
| SCHEMBL19849496 | 0.79 | MME (0.30) | POLBMMESMN1; SMN2L3MBTL1 | |
| SCHEMBL23802547 | 0.78 | MME (0.32) | MME | |
| SCHEMBL27104214 | 0.77 | POLB (0.42) | POLBMMEKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22571821 | 0.76 | POLB (0.33) | POLB | |
| SCHEMBL28452532 | 0.76 | MME (0.46) | POLBMMEALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL28452533 | 0.76 | MME (0.46) | POLBMMEALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL26781562 | 0.74 | PDCD1LG2 (0.35) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | POLB 1684/4885TRPA1 4876/4885MME 982/4885 |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | POLB 1684/4885TRPA1 4876/4885MME 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.